Alba Ariela Brandes

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Alba A Brandes
    Department of Medical Oncology, University Hospital of Padova, Padova, Italy
    J Clin Oncol 22:4779-86. 2004
  2. ncbi Long-term results of a prospective study on the treatment of medulloblastoma in adults
    Alba A Brandes
    Department of Medical Oncology, Azienda Unità Sanitaria Locale USL Bellaria Maggiore Hospital, Bologna, Italy
    Cancer 110:2035-41. 2007
  3. ncbi Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Bologna, Italy
    Cancer 115:3512-8. 2009
  4. ncbi A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Cancer 104:143-8. 2005
  5. ncbi How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
    A A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy
    Neurology 63:1281-4. 2004
  6. ncbi Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study
    Alba Ariela Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Cancer 101:2079-85. 2004
  7. ncbi Review of the prognostic factors in medulloblastoma of children and adults
    Alba A Brandes
    Medical Oncology Department, University Hospital, Via Gattamelata 64, 35100 Padova, Italy
    Crit Rev Oncol Hematol 50:121-8. 2004
  8. ncbi First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Alba A Brandes
    Department of Medical Oncology Direzione, Azienda Ospedale Università Ospedale Busonera, Via Gattamelata 64, 35100 Padua, Italy
    J Clin Oncol 22:1598-604. 2004
  9. ncbi Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
    A A Brandes
    Department of Medical Oncology and Neurological Sciences of Azienda Ospedale Università, Padua, Italy
    Ann Oncol 14:1727-31. 2003
  10. ncbi Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?
    Alba A Brandes
    Department of Medical Oncology, University Hospital, Padova, Italy
    Expert Rev Anticancer Ther 3:615-20. 2003

Detail Information

Publications51

  1. ncbi Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Alba A Brandes
    Department of Medical Oncology, University Hospital of Padova, Padova, Italy
    J Clin Oncol 22:4779-86. 2004
    ..The aim of the present multicenter phase II trial, therefore, was to ascertain the efficacy of second-line carmustine (BCNU) and irinotecan chemotherapy...
  2. ncbi Long-term results of a prospective study on the treatment of medulloblastoma in adults
    Alba A Brandes
    Department of Medical Oncology, Azienda Unità Sanitaria Locale USL Bellaria Maggiore Hospital, Bologna, Italy
    Cancer 110:2035-41. 2007
    ..Furthermore, the different therapeutic strategies used in these patients has made it difficult to assess survival rates and prognostic factors...
  3. ncbi Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Bologna, Italy
    Cancer 115:3512-8. 2009
    ....
  4. ncbi A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Cancer 104:143-8. 2005
    ..No data on the role of chemotherapy in recurrent ependymal tumors are available in adults. The aim of the current study was to investigate outcomes after salvage chemotherapy in this setting...
  5. ncbi How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
    A A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy
    Neurology 63:1281-4. 2004
    ..These drugs remain the standard chemotherapy for glioblastoma. However, because the criteria used to evaluate the activity of nitrosoureas in a neuro-oncologic setting have changed, new data on their activity are needed...
  6. ncbi Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study
    Alba Ariela Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Cancer 101:2079-85. 2004
    ..The aim of the current study was to evaluate the overall response rate, toxicity, and time to progression (TTP) with the use of standard PCV in this setting...
  7. ncbi Review of the prognostic factors in medulloblastoma of children and adults
    Alba A Brandes
    Medical Oncology Department, University Hospital, Via Gattamelata 64, 35100 Padova, Italy
    Crit Rev Oncol Hematol 50:121-8. 2004
    ..Great interest has been expressed in new biological and molecular prognostic factors, which, combined with clinical variables, may allow a more satisfactory stratification of patients...
  8. ncbi First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Alba A Brandes
    Department of Medical Oncology Direzione, Azienda Ospedale Università Ospedale Busonera, Via Gattamelata 64, 35100 Padua, Italy
    J Clin Oncol 22:1598-604. 2004
    ..The primary end point of the present multicenter phase II study was progression-free survival (PFS) at 6 months (PFS-6); secondary end points included response, toxicity, and overall survival...
  9. ncbi Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
    A A Brandes
    Department of Medical Oncology and Neurological Sciences of Azienda Ospedale Università, Padua, Italy
    Ann Oncol 14:1727-31. 2003
    ..This study was a phase II study of third-line chemotherapy with carboplatin plus teniposide in patients with recurrent oligodendroglioma...
  10. ncbi Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?
    Alba A Brandes
    Department of Medical Oncology, University Hospital, Padova, Italy
    Expert Rev Anticancer Ther 3:615-20. 2003
    ....
  11. ncbi The treatment of adults with medulloblastoma: a prospective study
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Int J Radiat Oncol Biol Phys 57:755-61. 2003
    ..To assess in a prospective trial the value of prognostic factors and the outcome of medulloblastoma in adults...
  12. ncbi Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Padova, Italy
    Oncology 63:38-41. 2002
    ....
  13. ncbi A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme
    A A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Padova, Italy
    Neurology 58:1759-64. 2002
    ....
  14. ncbi New strategy developments in brain tumor therapy
    A A Brandes
    Department of Oncology, Azienda Ospedale Universita, Padova, Italy
    Curr Pharm Des 7:1553-80. 2001
    ..5 cases per 100,000 inhabitants-years, and appears to increase with increasing age (1.2 % per year), with the greatest rate of increase in the population over age 70 years...
  15. ncbi Controversies in the therapy of low-grade glioma: when and how to treat
    Alba A Brandes
    Divisione di Oncologia Direzione Azienda Ospedale Università Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy
    Expert Rev Anticancer Ther 2:529-36. 2002
    ..Current concepts and future perspectives in the treatment of low-grade gliomas drawn from recent scientific literature are here summarized and discussed...
  16. ncbi A prospective study on glioblastoma in the elderly
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Padova, Italy
    Cancer 97:657-62. 2003
    ..Elderly patients (age > 65 years) with glioblastoma multiforme frequently are excluded from clinical studies, and prospective trials for patients with this age group do not exist to date...
  17. ncbi Changing boundaries in the treatment of malignant gliomas
    A A Brandes
    Divisione di Oncologia Direzione Azienda Ospedale Universita, Via Giustiniani 2, 35100 Padova, Italy
    Expert Rev Anticancer Ther 1:357-70. 2001
    ....
  18. ncbi Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Alba A Brandes
    Department of Medical Oncology, Ospedale Bellaria Maggiore, Bologna, Italy
    Cancer Chemother Pharmacol 64:769-75. 2009
    ..Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide...
  19. ncbi The development of platinum compounds and their possible combination
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 60:59-75. 2006
    ..This review analyses a part of these platinum compounds analyzed to date, their mechanism of action, resistance and the future trends in this sector...
  20. ncbi State-of-the-art treatment of high-grade brain tumors
    Alba A Brandes
    Medical Oncology Department, Azienda Ospedale-Universit, Padova, Italy
    Semin Oncol 30:4-9. 2003
    ..Additional randomized, controlled trials are needed to fully define the best option for first-line chemotherapy in both the adjuvant and recurrent settings in patients with high-grade malignant glioma...
  21. ncbi Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
    A Tosoni
    Department of Medical Oncology, Bellaria Maggiore Hospital, Via Altura 3, 40139, Bologna, Italy
    J Neurooncol 89:179-85. 2008
    ..Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy...
  22. ncbi MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda Unità Sanitaria Locale of Bologna, Bologna, Italy
    J Clin Oncol 26:2192-7. 2008
    ..The radiologic images obtained in this setting can be difficult to interpret since they may show radiation-induced pseudoprogression (psPD) rather than disease progression...
  23. ncbi Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma
    Alba A Brandes
    Department of Medical Oncology, Istituto Oncologico Veneto IRCCS Padova, Padova, Italy
    Neuro Oncol 8:253-60. 2006
    ..Even if no survival advantage has been demonstrated for temozolomide versus PCV, we conclude that temozolomide should be preferred because of its greater tolerability...
  24. ncbi Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status
    Alba A Brandes
    Department of Medical Oncology, Azienda USL Bellaria Maggiore Hospital, Bologna, Italy
    J Clin Oncol 27:1275-9. 2009
    ....
  25. ncbi Prevalence of breast cancer in women with breast complaints. Retrospective analysis in a population of symptomatic patients
    Franco Lumachi
    Endocrine Surgery Unit, Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, Via Giustiniani, 2, 35128 Padova, Italy
    Anticancer Res 22:3777-80. 2002
    ..The aim of the present study was to analyze whether any correlation exists between breast complaints and the risk of having or developing breast cancer (BC) in a population of self-selected women...
  26. ncbi The treatment of elderly patients with high-grade gliomas
    Alba A Brandes
    Medical Oncology Department, Azienda Ospedale-Universit, Padova, Italy
    Semin Oncol 30:58-62. 2003
    ..Results from larger prospective trials will determine the optimal role of chemotherapy, particularly temozolomide, in elderly patients with malignant gliomas...
  27. ncbi Adjuvant chemotherapy in the treatment of high grade gliomas
    Sara Lonardi
    Department of Medical Oncology, Padova University Hospital, Via Gattamelata 64, 35128 Padua, Italy
    Cancer Treat Rev 31:79-89. 2005
    ..Randomized comparisons with nitrosoureas are lacking and represent a major issue to be studied in future phase III trials...
  28. ncbi Breast cancer risk in symptomatic women spontaneously undergoing clinical breast examination
    Franco Lumachi
    Endocrine Surgery Unit, Department of Surgical and Gastroenterological Sciences, University of Padua, Medical School, 35128 Padova, Italy
    Anticancer Res 23:3565-8. 2003
    ..80-1.80), and no risk in those with breast pain (OR = 0.86, 95% CI 0.54-1.36) and nipple discharge (OR = 0.8, 95% CI 0.37-1.74). In conclusion, a relationship between breast complaints and the onset of BC does not seem to exist...
  29. ncbi EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
    Alba A Brandes
    Bellaria and Maggiore Hospitals, Bologna, Department of Medical Oncology, Italy
    Eur J Cancer 46:348-54. 2010
    ....
  30. ncbi Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer
    Franco Lumachi
    Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, 35128 Padova, Italy
    Anticancer Res 24:3221-4. 2004
    ....
  31. ncbi Treatment of brain metastases in uncommon tumors
    Alicia Tosoni
    Department of Medical Oncology, Azienda Ospedale, University of Padova, Italy
    Expert Rev Anticancer Ther 4:783-93. 2004
    ..Chemotherapy could be useful in patients with asymptomatic brain metastases and uncontrolled extracranial disease, depending on performance status and previous chemotherapy received...
  32. ncbi Current clinical management of gastrointestinal stromal tumors
    Alicia Tosoni
    Department of Medical Oncology, Azienda Ospedale, University of Padova, Italy
    Expert Rev Anticancer Ther 4:595-605. 2004
    ..However, the optimal dose and role of imatinib in an adjuvant or neoadjuvant setting have yet to be defined. Therefore, further studies investigating the mechanism of resistance to imatinib in patients with GIST are warranted...
  33. ncbi Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET)
    Alba A Brandes
    Department of Medical Oncology, Azienda USL Bellaria Maggiore Hospital Bologna, Italy
    Crit Rev Oncol Hematol 71:165-79. 2009
    ..An important challenge for the future will be the biological characterization of medulloblastoma, with the identification of specific genetic patterns of patients with a better or a worse prognosis...
  34. ncbi Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, AUSL Bologna, Bologna, Italy
    Neuro Oncol 10:361-7. 2008
    ..The potential pitfalls in clinical studies attempting to make a differential diagnosis between radionecrosis and disease progression are also discussed...
  35. ncbi Prognostic factors for anaplastic astrocytomas
    Alessia Compostella
    Department of Medical Oncology, Istituto Oncologico Veneto IRCCS, Padova, Italy
    J Neurooncol 81:295-303. 2007
    ..Our knowledge in this field is still limited, and remains an issue of great concern...
  36. ncbi Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Via Altura 3, Bologna, Italy
    J Clin Oncol 24:4746-53. 2006
    ..The aim of this study was to evaluate correlations between 1p/19q deletions, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, and response rate to TMZ in this setting...
  37. ncbi Treatment options for recurrent glioblastoma: pitfalls and future trends
    Enrico Franceschi
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy
    Expert Rev Anticancer Ther 9:613-9. 2009
    ..New therapeutic strategies, such as targeted therapies and anti-angiogenic treatments that appear promising with regard to improving the results at the time of recurrence are discussed...
  38. ncbi Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies
    Lara Maria Pasetto
    Department of Medical Oncology, Azienda Ospedaliera, Universita, Padova, Italy
    Expert Rev Anticancer Ther 3:167-78. 2003
    ....
  39. ncbi Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome?
    Alicia Tosoni
    Department of Medical Oncology, Bellaria Maggiore Hospital, Via Altura 3, Bologna, Italy
    Crit Rev Oncol Hematol 68:212-21. 2008
    ..More recent drugs with a high impact on the clinical outcome of metastatic breast cancer patients, such as taxanes or trastuzumab, play only a limited role in the treatment of brain metastases...
  40. ncbi Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy
    Expert Rev Anticancer Ther 10:179-84. 2010
    ..New-generation tyrosine kinase inhibitors, which have a broader target, are now considered the key to treatment for breast cancer...
  41. ncbi O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
    Alba A Brandes
    Department of Medical Oncology, Azienda USL Bellaria Maggiore Hospital, Bologna, Italy
    Neuro Oncol 12:283-8. 2010
    ..MGMT methylation status determined at first surgery appears to be of prognostic value; however, it is not predictive of outcome following second surgery...
  42. ncbi Association between response to primary treatments and MGMT status in glioblastoma
    Enrico Franceschi
    Department of Medical Oncology, Azienda USL Bellaria Maggiore, Bologna, Italy
    Expert Rev Anticancer Ther 8:1781-6. 2008
    ..Therefore, future strategies in the treatment of glioblastoma patients will include stratification for MGMT methylation status, and various approaches based on epigenetic features are currently under investigation...
  43. ncbi Glioblastoma in adults
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda ASL, Bologna, Italy
    Crit Rev Oncol Hematol 67:139-52. 2008
    ..At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment...
  44. ncbi Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments
    Alba A Brandes
    Department of Medical Oncology, Azienda Unità Sanitaria Locale Bellaria Maggiore Hospital, Bologna, Italy
    Clin Cancer Res 14:957-60. 2008
    ..As with other targeted agents, prospective trials using specific criteria and standardized methods to evaluate tissue biomarkers are required to find predictors of EGFR inhibitors activity in high-grade glioma patients...
  45. ncbi The pathogenesis and treatment of brain metastases: a comprehensive review
    Alicia Tosoni
    Department of Medical Oncology, University Hospital of Padova, Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy
    Crit Rev Oncol Hematol 52:199-215. 2004
    ..A better understanding of the complex processes underlying the development of brain metastasis will enable us to develop more satisfactory targeted treatments...
  46. ncbi Is intra-arterial chemotherapy useful in high-grade gliomas?
    Umberto Basso
    Divisione di Oncologia Medica-Direzione, Ospedale Busonera, Via Gattamelata 64, Azienda Ospedale-Universita, 35100 Padova, Italy
    Expert Rev Anticancer Ther 2:507-19. 2002
    ....
  47. ncbi Recommendations for the management of malignant gliomas in the elderly
    Umberto Basso
    Department of Oncology, Ospedale Busonera, Azienda Ospedale Universita, Padova, Italy
    Expert Rev Anticancer Ther 3:643-54. 2003
    ..Peculiar features of malignant gliomas in the elderly and some practical recommendations of management will be presented and discussed in this review...
  48. ncbi Glioblastoma in the elderly: current and future trends
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy
    Crit Rev Oncol Hematol 60:256-66. 2006
    ..Temozolomide appears to be the best available chemotherapy in this population of patients...
  49. ncbi Non-cytotoxic therapies for malignant gliomas
    Umberto Basso
    Department of Medical Oncology, , Italy
    J Neurooncol 58:57-69. 2002
    ....
  50. ncbi Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies
    Fabio Girardi
    Department of Medical Oncology, Bellaria Maggiore Hospital, Via Altura 3, 40139 Bologna, Italy
    Oncologist 15:683-94. 2010
    ..In the present paper, the most frequent cardiovascular toxicities and their underlying mechanisms are investigated, with a view to providing indications for effective patient management...
  51. ncbi A multicenter study of the prognosis and treatment of adult brain ependymal tumors
    Michele Reni
    Department of Radiochemotherapy, San Raffaele Hospital Scientific Institute, Milan, Italy
    Cancer 100:1221-9. 2004
    ....